Could the New Anti-CGRP Monoclonal Antibodies Be Effective in Migraine Aura? Case Reports and Literature Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35268319/
1 Regional Referral Headache Center, Neurology Unit, University Hospital Tor Vergata, 00133 Rome, Italy. 2 Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy. 3 IRCCS Santa...
Conclusion: In this paper, we report two cases of patients suffering from migraine with and without aura, who reported a complete disappearance of aura or reduced aura duration and intensity while taking Galcanezumab or Erenumab, respectively. Then, we present a brief overview of the literature about the controversial relationship between CSD...
-
Dr Hamid4yrBecause of their large size, mAbs cannot easily cross the blood-brain barrier in high quantities, rendering the peripheral trigeminovascular system to likely be a major site of their action.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrTheoretically it should be.
A retrospective evaluation of the combination of erenumab and onabotulinum toxin A for the prevention of chronic migraine
Source : https://www.sciencedirect.com/science/article/abs/pii/S0303846722000816?via=ihub
Prior to the approval of , (onabot A) was the only Food and Drug Administration-approved erenumab onabotulinum toxin A chronic migraine preventive treatment. In this study, we assess the safety...
Conclusion: This retrospective case series showed a reduction in monthly migraine and headache days with the treatment combination of erenumab and onabot A compared to onabot A alone in patients with chronic migraine.
-
Dr Hamid4yrMigraine is a common disabling primary headache disorder with high prevalence and significant socioeconomic burden and personal impacts.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrWe need to have this validated so that insurances are more open to covering it.
Show More Comments
Establishing content validity for the migraine Global Impression Item (mGI-I) assessment: a modified single-item migraine symptom severity questionnaire - BMC Neurology
Source : https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-022-02626-0
Objective To establish content validity of a single-item, migraine-specific symptom severity questionnaire for completion by migraine patients, key family members (KFMs) of migraine patients, and Healthcare Professionals (HCPs) who treat...
Conclusions: This qualitative study of 45 total respondents across 3 subpopulations, established the content validity and appropriateness of the mGI-I in migraine patients, KFMs, and migraine-treating HCPs. The study specifically confirmed that the mGI-I is comprehensive, easily understood and answered for each respondent population.
-
Dr Hamid4yrMigraine is a common disabling primary headache disorder with high prevalence and significant socioeconomic burden and personal impacts.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrThis is good to know.
Acute Medication Use in Patients With Migraine Treated With Monoclonal Antibodies Acting on the CGRP Pathway: Results From a Multicenter Study and Proposal of a New Index
Source : https://www.frontiersin.org/articles/10.3389/fneur.2022.846717/full
IntroductionAssessing the impact of migraine preventive treatments on acute medication consumption is important in clinical evaluation. The number of acute medication intakes per each monthly migraine day (MMD) could provide...
Conclusions: We confirmed that MoAbs acting on CGRP pathway decrease acute migraine medication consumption. We proposed a new index that can be easily applied in clinical practice to quantify migraine burden and its response to acute medication. Our index could help optimizing migraine acute treatment in clinical practice.
-
Dr Hamid4yrAssessing the impact of migraine preventive treatments on acute medication consumption is important in clinical evaluation
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrThis is encouraging since that is the goal of prevention.
Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35272533/
1 Clinical Immunology, Amgen Inc., South San Francisco, CA, USA. 2 Global Biostatistical Sciences, Amgen, Inc. Thousand Oaks, CA, USA. 3 Translational Safety and Bioanalytical Sciences, Amgen, Inc. Thousand Oaks,...
Conclusions: This pooled analysis showed that immunogenicity had no meaningful clinical impact on efficacy or safety of erenumab in patients with migraine
-
Dr Hamid4yrimmunogenicity had no meaningful clinical impact on efficacy or safety of erenumab in patients with migraine
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrThis is great summary of trials.